Form 483

Custompax, Inc., dba Vitaganic Form 483, 2012-11-06

FDA issued a Form 483 to Custompax, Inc., dba Vitaganic on 2012-11-06 with 8 public-safe observations.

483· Form 483 issued8 observations

Custompax, Inc., dba Vitaganic · Fremont, United States · Issued November 6, 2012

Overview

  • 8 public-safe observations are available for this inspection.
  • 8 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

6 Nov 2012
21 CFR 111.25(a)

Procedures - calibrating instruments

Cited by Mark A Chen

6 Nov 2012
21 CFR 111.70(c)(2)

Specifications identity, purity strength, composition

Cited by Mark A Chen

6 Nov 2012
21 CFR 111.75(a)(1)(i)

Component - verify identity, dietary ingredient

Cited by Mark A Chen

6 Nov 2012
21 CFR 111.75(c)

Specifications met - verify; finished batch

Cited by Mark A Chen

6 Nov 2012
21 CFR 111.83(b)(1)

Reserve sample -container-closure system

Cited by Mark A Chen

Inspected site

CICustompax, Inc., dba VitaganicFremont, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 111.205(b)(1)Cited across public-safe Form 483 observations1x
21 CFR 111.25(a)Cited across public-safe Form 483 observations1x
21 CFR 111.255(c)Cited across public-safe Form 483 observations1x
21 CFR 111.560(b)Cited across public-safe Form 483 observations1x
21 CFR 111.70(c)(2)Cited across public-safe Form 483 observations1x
21 CFR 111.75(a)(1)(i)Cited across public-safe Form 483 observations1x
21 CFR 111.75(c)Cited across public-safe Form 483 observations1x
21 CFR 111.83(b)(1)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 8 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere